Natural Compounds in Moringa oleifera Leaves Targeting Estrogen Receptor Beta (ESR2) for PCOS treatment: Insight from In Silico Docking

Aslikh Lana Dina, Alin Robiah Al Adawiah, Ade Hilman Juhaeni

Abstract


Polycystic ovary syndrome (PCOS) is a health complication that often leads to infertility in women. PCOS, as a reproductive-metabolic disorder, is also related to breast cancer and other diseases. Nevertheless, there is no universal drug for PCOS treatment. Hence, exploring a new candidate’s drugs is crucial. Estrogen receptor beta (ESR2) has become a significant marker for PCOS and has the potential to be used as a target for PCOS treatment. This study aims to explore the potential use of moringa as a nutraceutical. This study provides in silico data of selected compounds (naringenin, gallic acid, quinic acid, quercetin, apigenin, and kaempferol) in moringa leaves as a candidate drug for PCOS treatment targeting ESR2. Naringenin and apigenin showed a noteworthy calculated binding affinity score from docking into ESR2 (<- 7kcal/mol). Protein-protein analysis and gene analysis showed that ESR2 is expressed in varying tissues. It strengthens the potential use of moringa as a nutraceutical. This study showed that Moringa leaves have the potential to be used as a complement to PCOS treatment.


Full Text:

PDF
rticle

References


  1. Koohnavard F, Ahmadi K, Eftekhar E, Edalatmanesh MA. Computational Screening of FDA-approved Drugs to Identify Potential Aromatase Receptor Inhibitors for Polycystic Ovary Syndrome. J Biomol Struct Dyn. 2023;41(24):5507–15519.
  2. Choudhury AA, Rajeswari VD. Polycystic ovary syndrome (PCOS) increases the risk of subsequent gestational diabetes mellitus (GDM): A novel therapeutic perspective. Life Sci. 2022;310:121069.
  3. Choudhury AA, Bhattarai A, Sahoo S, Roy SD, Laskar NA, Firoz A. In Silico drug discovery of Solanum torvum as a phytotherapeutic aromatase inhibitor for PCOS-induced infertility: A comparative study with FDA-approved drugs. Silico Res Biomed. 2025;1(100003):3050–7871.
  4. Liaqat I, Jahan N, Krikun G, Taylor HS. Genetic Polymorphism in Pakistani Women with Polycystic Ovary Syndrome. Reprod Sci. 2015;22(3):347–57.
  5. Zhou S, Wen S, Sheng Y, Yang M, Shen X, Chen Y, et al. Association of Estrogen Receptor Genes Polymorphisms with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis based on Observational Studies. Front Endocrinol. 2021;12(726184):1–13.
  6. Lang-Muritano M, Sproll P, Wyss S, Kolly A, Hürlimann R, Konrad D, et al. Early-Onset Complete Ovarian Failure and Lack of Puberty in a Woman With Mutated Estrogen Receptor β (ESR2). J Clin Endocrinol Metab. 2018;103(10):3748–56.
  7. Smith J, Read ML, Hoffman J, Brown R, Bradshaw B, Campbell C, et al. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression. Hum Mol Genet. 2016;25(9):1836–45.
  8. Hartman J, Ström A, Gustafsson JÅ. Estrogen receptor beta in breast cancer—Diagnostic and therapeutic implications. Steroids. 2009;74(8):635–41.
  9. Jia M, Dahlman-Wright K, Gustafsson JÅ. Estrogen receptor alpha and beta in health and disease. Best Pr Res Clin Endocrinol Metab. 2015;29(4):557–68.
  10. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ERβ Inhibits Proliferation and Invasion of Breast Cancer Cells. Endocrinology. 2001;142(9):4120–4130.
  11. Yu K, Huang ZY, Xu XL, Li J, Fu XW, Deng SL. Estrogen Receptor Function: Impact on the Human Endometrium. Front Endocrinol. 2022;13(827724):1–16.
  12. Frick KM, Fleischer AW, Schwabe MR, Abdelazim FA, Sem DS, Donaldson WA. Not your mother’s hormone therapy: Highly selective estrogen receptor beta agonists as next-generation therapies for menopausal symptom relief. Horm Behav. 2025;173(105773):1–41.
  13. Abbas G, Al Harrasi A, Hussain H, Hamaed A, Supuran CT. The management of diabetes mellitus: Imperative role of natural products against dipeptidyl peptidase-4, α-glucosidase, and sodium-dependent glucose co-transporter 2 (SGLT2). Bioorg Chem. 2019;5(86):305–15.
  14. Verma AR, Vijayakumar M, Mathela CS, Rao C V. In vitro and in vivo antioxidant properties of different fractions of Moringa oleifera leaves. Food Chem Toxicol. 2009;47(9):2196–201.
  15. Fungtammasan S, Phupong V. The effect of Moringa oleifera capsule in increasing breast milk volume in early postpartum patients: A double-blind, randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2022;16(100171):1–5.
  16. Vergara-Jimenez M, Almatrafi MM, Fernandez ML. Bioactive Components in Moringa Oleifera Leaves Protect against Chronic Disease. Antioxidants (Basel). 2017;6(4):1–1.
  17. Barakat IAH, Khalil WKB, Al-Himaidi AR. Moringa oleifera extract modulates the expression of fertility related genes and elevation of calcium ions in sheep oocytes. Small Rumin Res. 2015;130:67–75.
  18. Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Scie Rep. 2023;13:13398.
  19. Sahoo RN, Pattanaik S, Pattnaik G, Mallick S, Mohapatra R. Review on The Use of Molecular Docking as The First Line Tool in Drug Discovery and Development. Indian J Pharm Sci. 2022;84(5):1334–7.
  20. Yabuuchi H, Hayashi K, Shigemoto A, Fujiwara M, Nomura Y, Nakashima M, et al. Virtual screening of antimicrobial plant extracts by machine learning classification of chemical compounds in semantic space. PLoS One. 2023;18(5):1–12.
  21. Naaz S, Balramnavar VM, Kaur A. Medicinal Plant Databases: Analyzing Strengths, Weaknesses and Innovations for Future Improvements. Life Sci Res Commun. 2024;1(1):31–41.
  22. Mumtaz A, Masud A, Ayub N, Fatima Y, Shah M. The Significance of Anti-Mullerian Hormone in the Identification of Polycystic Ovarian Syndrome among Pakistani Women. J Soc Obs Gynaecol Pak [Internet]. 2023;13(3):293–7. Available from: https://jsogp.net/index.php/jsogp/article/view/652
  23. Narayana S, Ananad C, Kumari NS, Sonkusere S, Babu SVS. Impact of Aromatase Enzyme and its Altered Regulation on Polycystic Ovary Syndrome (PCOS): A Key Factor in Pathogenesis of PCOS. Indian J Med Spec. 2023;14(4):206–11.
  24. Smith JR, Bolton ER, Dwinell MR. The Rat: A Model Used in Biomedical Research. Methods Mol Biol. 2019;2018:1–41.
  25. Pike ACW, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li YL, et al. Structural Insights into the Mode of Action of a Pure Antiestrogen. Structure. 2001;9(2):p145-153.
  26. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12.
  27. Wang X, Lai J, Xu F, Liu M. Network Pharmacology and Molecular Docking: Exploring the Mechanism of Peppermint in Mastitis Prevention and Treatment in Dairy Cows. Vet Sci. 2025;12(2):1–19.
  28. Bugnon M, Röhrig UF, Goullieux M, Perez MAS, Daina A, Michielin O, et al. SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina. Nucleic Acid Res. 2024;52(W1):W324–W332.
  29. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021;61(8):3891–3898.
  30. Szklarczyk D, Nastou K, Koutrouli M, Kirsch R, Mehryary F, Hachilif R, et al. The STRING database in 2025: protein networks with directionality of regulation. Nucleic Acid Res. 2025;53(D1):D730–D737.
  31. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(42717):1–13.
  32. Daina A, Michielin O, Zoete V. iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach. J Chem Inf Model. 2014;54(12):3284–301.
  33. Daina A, Zoete V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem. 2016;11(11):1117–21.
  34. Filimonov DA, Lagunin AA, Gloriozova TA, Rudik A V., Druzhilovskii DS, Pogodin P V., et al. Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource. Chem Heterocycl Comp. 2014;50:444–57.
  35. El-Shehawi AM, Alkafafy M, El-Shazly S, Sayed S, Farouk S, Alotaibi S, et al. Moringa oleifera leaves ethanolic extract ameliorates high fat diet-induced obesity in rats. J King Saud Univ. 2021;33:101552–61.
  36. Kashyap P, Kumar S, Riar CS, Jindal N, Baniwal P, Guiné RPF, et al. Recent Advances in Drumstick (Moringa oleifera) Leaves Bioactive Compounds: Composition, Health Benefits, Bioaccessibility, and Dietary Applications. Antioxidants. 2022;11(402):1–37.
  37. Hamadou M, Bassogog CBB, Obadias FV, Assaly AD, Mune MAM. Moringa oleifera potential for the treatment and prevention of COVID-19 involving molecular interaction, antioxidant properties and kinetic mechanism. PLoS One [Internet]. 2025;20(12):e0337904. Available from: https://doi.org/10.1371/journal.pone.0337904
  38. Daeffler KNM, Lester HA, Dougherty DA. Functionally Important Aromatic-Aromatic and Sulfur-π Interactions in the D2 Dopamine Receptor. J Am Chem Soc. 2012;134(36):14890–14896.
  39. Gupta A, Hossain MM, Miller N, Kerin M, Callagy G, Gupta S. NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK–eIF2α–ATF4 signalling in breast cancer. Oncogene. 2016;35(45):5860–5871.
  40. Lebreton L, Boyer JC, Lafay-Chebassier C, Hennart B, Baklouti S, Cunat S, et al. French- Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten. Clin Pharmacol Ther. 2024;117(2):387–98.
  41. Xu R, Wang F, Yang H, Wang Z. Action Sites and Clinical Application of HIF-1α Inhibitors. Molecules. 2022;27(11):3426–40.
  42. Choi MK, Son S, Hong M, Choi MS, Kwon JY, Lee J. Maintenance of Membrane Integrity and Permeability Depends on a Patched-Related Protein in Caenorhabditis elegans. Genetics. 2016;202(4):1411–1420.
  43. Walsh AA, Szklarz GD, Scott EE. Human Cytochrome P450 1A1 Structure and Utility in Understanding Drug and Xenobiotic Metabolism. J Biol Chem. 2013;288(18):12932–12943.
  44. Yuan J, Li Z, Yu Y, Wang X, Zhao Y. Natural Compounds in The Management of Polycystic Ovary Syndrome: a Comprehensive Review of Hormonal Regulation and Therapeutic Potential. Front Nutr. 2025;12:1520695.
  45. Shah MZ ul haq, Shrivastva V kumar, Mir MA, Sheikh WM, Ganie MA, Rather GA, et al. Effect of Quercetin on Steroidogenesis and Folliculogenesis in Ovary of Mice with Experimentally-Induced Polycystic Ovarian Syndrome. Front Endocrinol. 2023;14:1153289.
  46. Shah MZUH, Soni M, Shrivastava VK, Mir MA, Muzamil S. Gallic Acid Reverses Ovarian Disturbances in Mice with Letrozole-induced PCOS via Modulating Adipo R1 Expression. Toxicol Rep. 2022;20(9):1938–49.
  47. Peng F, Hu Y, Peng S, Zeng N, Shi L. Apigenin Exerts Protective Effect and Restores Ovarian Function in Dehydroepiandrosterone Induced Polycystic Ovary Syndrome Rats: a biochemical and Histological Analysis. Ann Med. 2022;54(1):578–87.
  48. Wu YX, Yang XY, Han BS, Hu YY, An T, Lv BH, et al. Naringenin Regulates Gut Microbiota and SIRT/PGC-1ɑ signaling pathway in rats with letrozole-induced polycystic ovary syndrome. Biomed Pharmacother. 2022;153:113286.




DOI: https://doi.org/10.20961/jbb.v6i1.115073

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Print ISSN: 2775-5223
Online ISSN: 2808-3229
Website: https://jurnal.uns.ac.id/jbb
Email: jurnal.biotek.biodiv@mail.uns.ac.id
Published by: Universitas Sebelas Maret
Jl. Ir. Sutami Street, No. 36A, Surakarta, Jawa Tengah 57126